Tradestie Institutional Equity Comparison Engine
NDRA vs CDNA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CDNA Overall Edge
CDNA Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CareDx, Inc. (CDNA) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NDRA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CDNA at 47.1x Forward P/E and 1.6% operating margin (+39.3% YoY). In options structure, NDRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CDNA sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CDNA
NDRA N/M vs CDNA 47.1x Fwd P/E
Growth & Margin Winner
CDNA
Op Margin 0.0% vs 1.6% ยท YoY +0.0% vs +39.3%
Momentum & Technical Winner
CDNA
1Y -32.7% vs +364.5% ยท 52W Pos 37% vs 77%
Options & Structure Winner
CDNA
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (18th %ile IV)
NDRA
NASDAQ
ENDRA Life Sciences Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
+0.23% 1D
Market Cap
$6.6M
1M Return
-6.75%
1Y Return
-32.72%
Forward P/E
N/M
Unified AI Score
44.7 / 100
HOLD
Tech 35.0
Fund 46.0
Flow 50.0
Mom 60.0
CDNA
NASDAQ
CareDx, Inc.
Services-Medical Laboratories
$73.72
-5.34% 1D
Market Cap
$4.1B
1M Return
+15.19%
1Y Return
+364.52%
Forward P/E
47.1x
Unified AI Score
24.5 / 100
STRONG SELL
Tech 15.0
Fund 36.0
Flow 70.0
Mom 25.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NDRA -32.72%
CDNA +364.52%
Spread: +397.24 pp (CDNA Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NDRA Revenue | CDNA Revenue | NDRA Op. Margin | CDNA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $80M | -146080.5% | -20.3% | CDNA |
| FY2019 | N/A | $130M | N/A | -19.3% | CDNA |
| FY2020 | N/A | $190M | N/A | -11.7% | CDNA |
| FY2021 | N/A | $300M | N/A | -10.0% | CDNA |
| FY2022 | N/A | $320M | N/A | -24.0% | CDNA |
| FY2023 | N/A | $280M | N/A | -72.5% | CDNA |
| FY2024 | N/A | $330M | N/A | 12.2% | CDNA |
| FY2025 | N/A | $380M | N/A | -8.1% | CDNA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NDRA | CDNA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.6M | $4.1B | Larger Scale | CDNA |
| Trailing P/E Ratio Valuation | N/M | 32.9x | Lower Multiple | CDNA |
| Forward P/E Ratio Valuation | N/M | 47.1x | Lower Multiple | CDNA |
| Revenue Growth (YoY) Growth | +0.0% | +39.3% | Higher Growth | CDNA |
| Operating Margin (TTM) Profitability | 0.0% | 1.6% | Higher Margin | CDNA |
| Net Profit Margin Profitability | 0.0% | 25.9% | Higher Margin | CDNA |
| Return on Equity (ROE) Capital Efficiency | -152.0% | 33.0% | Higher ROE | CDNA |
| 52-Week Range Position Momentum | 37% ($3โ$7) | 77% ($15โ$91) | Stronger Trend | CDNA |
| Beta / 30D Volatility Risk Regime | 0.71ฮฒ ยท 48% Vol | 1.21ฮฒ ยท 98% Vol | Lower Realized Risk | NDRA |
| Unified Institutional Score Composite Signal | 44.7 / 100 (HOLD) | 24.5 / 100 (STRONG SELL) | Higher Composite | NDRA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NDRA vs CDNA Buy Guide
NDRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CDNA
CONSOLIDATION
30d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
18th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NDRA nor CDNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.